Lung Cancer | Specialty

The lung cancer condition center is a comprehensive resource for clinical news and expert insights on lung cancer. Read more at OncLive.

Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism

May 31st 2025

Amivantamab/chemotherapy demonstrated sustained efficacy, despite the osimertinib resistance mechanism in patients with EGFR-mutated NSCLC.

Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

May 31st 2025

Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.

Adjuvant Chemotherapy Improves DFS in Molecularly Higher-Risk NSCLC

May 31st 2025

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Pooled Data for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Addressing CNS Involvement in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Selecting a TKI in ROS1+ NSCLC Management

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Treatment Sequencing Decisions in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30th 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

The Prevalence of ROS1 Fusions in Advanced NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI

May 30th 2025

Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.

BLA Is Withdrawn for Patritumab Deruxtecan in EGFR-Mutated NSCLC

May 29th 2025

The BLA seeking the approval of patritumab deruxtecan in EGFR-mutated non–small cell lung cancer has been voluntarily withdrawn.

Expert Insights in the Management of Early-Stage NSCLC With Limited Nodal or Oligometastatic Disease

May 29th 2025

Panelists discuss how advanced radiotherapy techniques, including stereotactic body radiation therapy (SBRT), combined with immunotherapy, have emerged as preferred treatment approaches for unresectable early-stage non–small cell lung cancer (NSCLC).

Expert Insights and Best Practices in the Diagnosis of Unresectable Early-Stage NSCLC

May 29th 2025

Panelists discuss how the diagnostic workup for unresectable stage III non–small cell lung cancer (NSCLC) requires comprehensive staging including imaging studies (PET-CT, brain MRI), tissue sampling through bronchoscopy or endobronchial ultrasound (EBUS), molecular and biomarker testing, and multidisciplinary evaluation to guide optimal treatment planning.

FDA Grants Priority Review to Sevabertinib for HER2-Mutant NSCLC

May 28th 2025

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer

May 28th 2025

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

Early Insights from ASCO 2025: Press Briefing Highlights with Clinical Impact

May 26th 2025

A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.

Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

May 23rd 2025

Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.